Key result
Single-dose roxithromycin selectively reduces plasma aldosterone in patients with KCNJ5-mutated aldosterone-producing adenomas.
Why the study?
KCNJ5 mutations in aldosterone-producing adenomas render aldosterone synthesis sensitive to macrolides in vitro, but whether roxithromycin reduces plasma aldosterone concentration and blood pressure in patients was unknown.
Does a single oral dose of roxithromycin reduce plasma aldosterone concentration and blood pressure in patients with KCNJ5-mutated aldosterone-producing adenoma?
Does a single oral dose of roxithromycin reduce plasma aldosterone concentration and blood pressure in patients with KCNJ5-mutated aldosterone-producing adenoma?
A single dose of roxithromycin selectively suppresses aldosterone secretion in KCNJ5-mutated aldosterone-producing adenomas, serving as a potential functional marker for precision subtyping of primary aldosteronism.
Answers are grounded in this paper and cite their sources.
May support roxithromycin as a functional marker for KCNJ5-mutated APA; leaves open its role in precision subtyping pending validation.
OBJECTIVE: Primary aldosteronism (PA), the most common curable form of hypertension, is frequently caused by aldosterone-producing adenomas (APAs) harboring KCNJ5 mutations that render aldosterone synthesis sensitive to macrolides in vitro. This study aimed to evaluate whether a single dose of roxithromycin reduces plasma aldosterone concentration (PAC) and blood pressure (BP) in patients with KCNJ5-mutated APA, and to characterize the haemodynamic effects of macrolides in mice. DESIGN: Prospective, within-patient pharmacologic challenge. METHODS: At the specialized Hypertension Center, University of Padua, eligible consecutive hypertensive patients screened for PA underwent a pharmacologic challenge with a single oral dose of roxithromycin to investigate the within-patient changes in plasma aldosterone concentration (PAC), active renin, cortisol, and blood pressure (BP). RESULTS: Among 373 challenged patients, 18 had KCNJ5 (G151R or L168R) -mutated APA, 25 had wild-type APA, and 307 had no PA. Roxithromycin reduced PAC (P<0.001) only in APA with KCNJ5 mutation, albeit it did not lower BP values. However, it produced a small BP decrease in non-PA hypertensive patients. Mouse studies showed that this BP-lowering can be due to macrolides-induced attenuation of angiotensin II actions and enhancement of endothelium- and nitric oxide-dependent vasodilation. CONCLUSIONS: The selective suppression of aldosterone secretion with roxithromycin in KCNJ5-mutated APA in vivo, which aligns with ex-vivo mechanistic data, can represent a functional marker of KCNJ5 mutations and could help guide precision subtyping of PA patients. Macrolides also exhibit an aldosterone-independent antihypertensive effect in non-PA patients, which involves nitric oxide-dependent vasodilation.
No takes yet. Share an insight, caveat, or question.
Rossi et al. (2026) studied Hypertension / Primary aldosteronism (n=373). Roxithromycin vs. Baseline (within-patient changes) was evaluated on Within-patient changes in plasma aldosterone concentration (PAC) (p=<0.001). A single oral dose of roxithromycin selectively reduced plasma aldosterone concentration in patients with KCNJ5-mutated aldosterone-producing adenomas.
Synapse has enriched 10 related papers. Consider them for comparative context: